For years, Novo Nordisk was a discreet and little-known pharmaceutical firm centered on the world of diabetes. However all the pieces modified with the growth in weight-loss therapies. Because of Ozempic and Wegovy, the Danish firm turned probably the most invaluable in Europe, even surpassing Nestlé and LVMH.
📉 Nevertheless, in current months it has misplaced greater than 56% of its inventory market worth. A key alliance in america was damaged, competitors from Eli Lilly turned fierce, regulators started asking questions… and the magic began to falter.
On this video, we let you know the total story behind the rise and fall of Novo Nordisk, what is going on with the well-known GLP-1 medication, and whether or not this inventory market drop is a novel funding alternative… or a traditional market entice.
Try our earlier movies! ⬇️
🔴The BIGGEST INDUSTRIAL FAILURE of the USA?
https://youtu.be/cLRmzfvTGms
🔴Adobe is PLUNGING 40%… Are we dealing with a brand new KODAK case?
https://youtu.be/Y3ZKjHd_kEA
🔴Can We Compete? Chinese language Corporations are Giving Up Earnings
https://youtu.be/u13e1VFNZLk
✉️ Enterprise Enquiries → group@visualeconomik.com
source